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Received May 23, 2013; accepted July 31, 2013AbstractBackground: We conducted a Phase II study of biweekly oxaliplatin plus oral tegafur-uracil in the preoperative chemoradiotherapy (CRT) for
locally advanced resectable mid-to-lower rectal cancer in our hospital, to evaluate the feasibility of this drug combination in tumor pathologic
response, acute toxicity, local control, disease-free survival (DFS), overall survival (OS), and time to distant metastasis in an Asian cohort.
Methods: Twenty patients with histopathologically confirmed rectal cancer (Stage IIeIII) were enrolled in the study. Radiotherapy of 50 Gy was
delivered in 25 fractions of 2 Gy, one fraction/day, five fractions/week, for 5 weeks. Oxaliplatin 55 mg/m2 was administered intravenously for 60
minutes on Day 1 every 2 weeks, and tegafur-uracil 350 mg/m2 was given orally everyday during the whole radiotherapy course, including
holidays. Surgery was scheduled 6 weeks after completion of the preoperative chemoradiotherapy. The primary endpoint was to determine the
pathologic complete response (pCR) rate after this neoadjuvant chemoradiotherapy. The secondary endpoint was to determine the treatment-
related toxicity profile, local control, DFS, OS, and time to metastasis.
Results: All patients underwent a complete course of preoperative chemoradiotherapy. There was no local recurrence during the study period.
The complete resection rate was 20/20 (100%) and the close resection margin rate was 3/20 (15%). The pCR rate was 8/20 (40%). During
chemoradiotherapy, the most frequent toxicity was diarrhea 9/20 (45% of patients, grade 2 in 3/20, 15%). There were no grade 3 or higher
hematologic or non-hematologic events or treatment-related deaths. The 3-year OS and DFS rates were 94.1% and 78.6%, respectively.
Conclusion: Preoperative chemoradiotherapy with oxaliplatin and tegafur-uracil was well-tolerated and achieved an excellent pCR in our pa-
tients with locally advanced mid-to-lower rectal cancer.
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Colorectal cancer is a major health problem in Taiwan. The
annual incidence of colorectal cancer has increased up to
43.5% in the past 10 years, with >8000 new cases of colon
cancer and >2600 new cases of rectal cancer each year.
Because of the unique anatomic location of rectal cancer, ithinese Medical Association. All rights reserved.
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mesorectal excision (TME) can reduce the local recurrence
rate to < 10%. Abdominoperineal resection is the standard
treatment for distal rectal cancer. However, it has significant
disadvantages of anal sphincter sacrifice with permanent co-
lostomy and a high incidence of sexual and urinary
dysfunction.
Although TME has markedly improved the local control of
locally advanced distal rectal cancer, the addition of pelvic
radiation concomitant with fluorouracil (5-FU) chemotherapy
had provided further improvement in pelvic local control ac-
cording to the Dutch trial.1 Many Phase II studies have shown
higher rates of complete pathologic responses after chemo-
radiotherapy compared with radiation alone.2,3 The German
Rectal Cancer Study Group Phase III study further demon-
strated the advantages of preoperative chemoradiotherapy over
postoperative chemoradiotherapy in acute toxicity, anal
sphincter preservation, and local control.4e6 Studies are now
focused on the use of radiosensitizers in combination with 5-
FU to determine whether this newly developed preoperative
treatment will provide better results than the conventional 5-
FU-based chemoradiotherapy. Tegafur-uracil is a composite
drug composed of 100 mg tegafur and 224 mg uracil (molar
ratio 1:4). It is an attractive oral form of 5-FU and is marketed
as tegafur-uracil in Taiwan. Tegafur, a prodrug of 5-FU, is
easily absorbed though the gastrointestinal tract and slowly
metabolized to 5-FU, mainly in the liver. Tegafur given with
radiotherapy for patients with rectal cancer showed signifi-
cantly less hematologic toxicity without significant treatment
outcome difference with 5-FU.7 Uracil is an inhibitor of
dihydropyrimidine dehydrogenase, the rate-limiting enzyme
of 5-FU degradation. A stably high concentration of tegafur-
uracil is expected to be maintained in the liver and in circu-
lation. It has been approved for treatment of advanced gastric
cancer and colorectal cancer, which are usually treated with 5-
FU-based chemotherapy in Taiwan.
Oxaliplatin is a platinum derivative which has shown
radiosensitizing properties and synergism with 5-FU. Clinical
studies have shown high response rates for the combination of
oxaliplatin with either 5-FU or radiation therapy. Furthermore,
the addition of oxaliplatin to a biweekly regimen with 5-FU
proved manageable and beneficial in patients with metastatic
colorectal cancer.8 Recently, several investigators have re-
ported that the combination of oxaliplatin with fluoropyr-
imidines in preoperative chemoradiotherapy is associated with
a pathologic complete response (pCR) of about 15e29% in
locally advanced rectal cancer.9e11
To achieve downstaging and better resectability in locally
advanced or low rectal cancer, preoperative chemo-
radiotherapy with 5-FU has become the standard of treatment.
However, the pCR is still unsatisfactory. We conducted a
Phase II study of biweekly oxaliplatin plus oral tegafur-uracil
in the preoperative chemoradiotherapy for resectable rectal
cancer in a single institute, to evaluate the tumor pathologic
response, acute toxicity, local control, disease-free survival
(DFS), overall survival (OS), and time to distant metastasis in
an Asian cohort.2. Methods2.1. Study design and patientsThis open-label, single arm, Phase II study was conducted
in a single institute and approved by the hospital’s institutional
review board. Each patient provided written informed consent
before participating in the study.
Eligible patients were those aged 18e75 years, with path-
ologically confirmed rectal adenocarcinoma with an inferior
margin no more than 10 cm above the anal verge, including
anorectal junction tumor, as assessed by a lower GI scope. The
clinical stage was defined according to AJCC 2002 TMN
staging by computed tomography (CT) scan or magnetic
resonance imaging (MRI) of the pelvis, chest X-ray, whole-
body bone scan, or positron emission tomography (PET)
scan. Further inclusion criteria were Karnofsky performance
scale (KPS)  70%, and adequate hematological, liver, and
renal functions.12
Exclusion criteria included metastatic disease when diag-
nosed, prior chemotherapy or radiotherapy to the pelvic area,
other cancers, contraindication for administration of oxali-
platin or tegafur-uracil, pregnancy or nursing, and refusing
radical operation after preoperative chemoradiotherapy.2.2. Treatment planAfter urine voiding, the patients were advised to intake
300 mL of water. Thirty minutes later, the patients underwent
CT simulation in the supine position with immobilization with
a vacuum cushion. Identical urine voiding and immobilization
procedures were taken for each fraction of radiotherapy.
PTVG was defined as gross tumor volume with 5e10 mm
margin, and PTVC as clinical tumor volume (CTV) with
8e10 mm margin. Gross tumor volume consisted of gross
rectal tumor and pelvic lymphadenopathy, and CTV consisted
of internal iliac lymph node below the L5-S1 spine level,
mesorectum, perirectal fat, and the presacral space. For T4
tumor, an external iliac lymph node was also included in CTV.
Radiotherapy consisted of a total of 50e50.4 Gy to planning
target volume of gross tumor (PTVG) and 45 Gy to planning
target volume of clinical and subclinical tumor volume
(PTVC) delivered as 10e15 MV photons in 25 fractions, of
2 Gy/fraction, five fractions/week, delivered by a seven-field
intensity-modulated technique with five to seven fields. The
treatment machine was a VARIAN Clinac 21EX, and planning
software was Eclipse Version 10 (Varian Medical Systems
Inc., Palo Alto, CA 94304, USA).
During the whole radiotherapy course, concurrent chemo-
therapy with oxaliplatin 55 mg/m2 was administered intrave-
nously for 60 minutes on Day 1 every 2 weeks, and tegafur-
uracil 350 mg/m2 was given orally every day, including
weekends and holidays.
Radical surgery was performed in all of the patients ac-
cording to a standardized technique 6e8 weeks after preop-
erative chemoradiotherapy was completed (Fig. 1). One of the
two standard procedures, anterior resection with the TME
Fig. 1. Treatment course of preoperative chemoradiotherapy. Radiotherapy was delivered in 25 fractions, one fraction/day (five fractions/week) for 5 weeks.
Oxaliplatin was administrated intravenously for 60 minutes on Day 1 every 2 weeks, and tegafur-uracil was given orally during the whole radiotherapy course,
including holidays.
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according to tumor extension and individual situation.
During radiotherapy, side effects were monitored and com-
plete blood cell count/differential blood count (CBC/DC) and
sequential multiple biochemical analysis of blood (SMA) were
checked weekly. NCI Common Toxicity Criteria and Toxicity
Criteria of the Radiation Therapy Oncology Group were
employed in the evaluation of toxicity. Therapeutic effects were
determined by pathological evaluation of radical surgery.
Pathologic response of tumor regression (TRG) was graded
according to a method described by Dworak et al13 for the
assessment of the pathologic response after preoperative che-
moradiotherapy in rectal cancer on a scale from zero to four,
based on the presence of residual tumor cells and the extent of
fibrosis.2.3. Statistical considerationsTable 1
Patient characteristics.The primary endpoint of this study was to determine the
efficacy of oxaliplatin, tegafur-uracil, and radiotherapy by
pathologic response, and the second endpoint was to determine
the toxicity associated with this combination, local control,
DFS, OS, and time to metastasis. The treatment efficacy was
primarily measured by tumor regression grade. Descriptive
statistics were reported as proportions and medians.
KaplaneMeier analysis was used to estimate DFS and OS.
3. Results
No. of patients %
Patients 20 1003.1. Patient characteristics
Age (y)
Median (range) 60.5 (47e70)
Sex
Male 11 55
Female 9 45
BMI (kg/m2)
Median (range) 24 (18e28)
Performance status
Karnofsky
90 7 35
80 13 65
TN clinical staging
T2N0 3 15
T3N0 3 15A total of 20 patients were enrolled in the study from
January 2008 to May 2009. There were 11 males and nine
females. All patients had newly diagnosed rectal cancer and no
evidence of distant metastases when diagnosed. The median
age was 60.5 years (range 26e70 years). The clinical T and N
stages were determined by CT (n ¼ 14) or MRI (n ¼ 6) scan
according to AJCC 2002 staging system. Clinical T stages
were T2(4), T3(12), and T4(6), and clinical N stages were
N0(8), N1(9), N2(5), as shown in Table 1. In 15 patients, the
tumor was located 0e5 cm from the anal verge. Patient
characteristics are listed in Table 1.T4N0 1 5
T3N1-2 9 45
T4N1 4 203.2. Response and survival
Distance from anal verge
5 cm 13 65
5e8 cm 7 35As shown in Table 2, tumor regression grade (TRG) 4 was
found in eight patients (40%), TRG3 in four patients (20%),TRG2 in seven patients (35%), and TRG0 in one patient (5%).
With a median follow-up of 38 months, the 3-year OS rate was
94.1% and the 3-year DFS rate was 78.6%. DFS and OS are
shown in Fig. 2. Sixteen patients (80%) were disease-free and
four patients (20%) relapsed, all with distant metastasis alone.
None of the patients developed local recurrence. First-
diagnosed distant metastases were located in the liver (two
patients), lung (two patients), and brain (one patient). One
patient was diagnosed as having distant recurrence with
simultaneous brain and lung metastasis. In distant-failure pa-
tients, median time to distant recurrence was 7.5 months.3.3. Treatment complianceAll patients received the scheduled radiotherapy dose to
PTVG and PTVC. The median treatment time was 35 days
(range 32e43 days). All patients received the planned oxali-
platin and tegafur-uracil doses. The median time from
completion of chemoradiotherapy to surgery was 43 days
(range 33e50 days). Eleven patients underwent coloanal
anastomosis, five patients underwent lower anterior resection of
rectal tumor, and four patients underwent abdominoperineal
resection with permanent colostomy. The sphincter-
preservation rate was 16/20 (80%) in all patients, and 9/13
(69%) in patients with tumor seated 5 cm from the anal verge.
Table 2
Parameters after preoperative chemoradiotherapy and radical surgery (n ¼ 20).
Parameter No. of patients %
Tumor regression grade
0 1 5
2 7 35
3 4 20
4 8 40
Types of surgery
Low anterior resection 5 25
Coloanal anastomosis 11 55
Abdominoperineal resection 4 20
Number of harvested lymph nodes
Median (range) 10.5 (2e24)
Surgical complication
Anastomosis leakage 1 5
Mortality 0 0
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with pus formation. The anastomosis condition was controlled
after antibiotics treatment and wound debridement, and closure
of ileostomy was performed smoothly 6 weeks later.Fig. 2. Overall survival (upper) and disease-free survival (lower) for all pa-
tients (n ¼ 20).3.4. ToxicityToxicities were mild to moderate in intensity and easily
managed. There were no grade 3 or higher hematologic or
non-hematologic events. The most frequent toxicity was
diarrhea (9/20, 45% of patients, grade 2 in 3/20, 15%), fol-
lowed by asthenia (5/20, 25%), neutropenia (5/20, 25%),
constipation (5/20, 25%), nausea (2/20, 10%), and vomiting
(2/20, 10%), shown in Table 3.
4. Discussion
The response of preoperative chemoradiotherapy in rectal
cancer has a significant impact on prognosis. Many clinical
trials have assessed the treatment effects of preoperative
chemoradiotherapy. Oxaliplatin is widely used in the post-
operative adjuvant setting, and has also been applied in pre-
operative treatment.14
Some clinical trials showed that the addition of oxaliplatin
increased toxicity without primary tumor response benefit.
Aschele et al15 conducted a Phase III trial in 2011, in which
radiotherapy was administrated concurrently with daily infu-
sional 5-FU 225 mg/m2 and, for the experimental arm, addi-
tional weekly intravenous oxaliplatin 60 mg/m2 for 2 hours.
After preoperative CRT, the pCR rates were both 16% with or
without oxaliplatin. The grade 3e4 toxicity of the oxaliplatin
group was 24%, and that of the control group was 8%. The
compliances for radiotherapy and chemotherapy were only
84% and 66%, respectively. Poor compliance indicated that
the chemotherapy regimen was too toxic, so treatment was
discontinued. This might have compromised primary tumor
response and diminished the benefit of oxaliplatin.
By contrast, some clinical trials showed positive results. In
the German CAO/ARO/AIO-04 randomized Phase III trial,
chemotherapy with infusional 5-FU (250 mg/m2 Days 1e14
and Days 22e35) and oxaliplatin (50 mg/m2 Day 1, Day 8,
Day 22, and Day 29) was given concurrently with radio-
therapy.16 Better pCR was observed in the oxaliplatin group
than the control group (17% vs. 13%, p ¼ 0.038). Although
the grade 3e4 toxicities of the control group and oxaliplatin
group were similar (20% vs. 23%), the compliances of
radiotherapy and chemotherapy were 94% and 85%, respec-
tively in the oxaliplatin group.Table 3
Toxicity profile (n ¼ 20).
Toxicity NCI-CTC grade (%)
Grade 1 Grade 2 Grade 3 Grade 4
Neutropenia 4 (20) d d d
Febrile neutropenia d d d d
Thrombocytopenia d d d d
Diarrhea 6 (30) 3 (15) d d
Constipation 4 (20) d d d
Nausea 2 (10) d d d
Vomiting 2 (10) d d d
Fatigue 5 (25) d d d
Neurotoxicity 4 (20) d d d
NCI-CTC ¼ National Cancer Institute Common Toxicity Criteria.
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necessary to achieve a tolerable combination of treatments.
Treatment compliance is important to gain treatment benefit. In
our study, oxaliplatin 55 mg/m2 every 2 weeks and daily
tegafur-uracil 250e350 mg/m2 were given concurrently with
radiotherapy and all of our patients tolerated the treatment
well. There were no grade 3 or above adverse events. The only
hematologic side effect was neutropenia (4/20, 20%), and all of
the cases were grade 1 and short-lasting, without neutropenic
fever. The most common side effect was grade 1e2 diarrhea,
which was manageable with medication. Only grade 1 neuro-
toxicity was observed in four (20%) patients. The profiles of
side effects were consistent with those in previous studies. All
patients completed the full course of chemotherapy and
radiotherapy. The treatment results were compatible with those
of similar studies. After preoperative chemoradiotherapy, the
pCR rate, and the 3-year OS and DFS rates were 8/20 (40%),
94.1%, and 78.6%, respectively, which were markedly better
than those (12.5%, 4-year 74.5%, and 4-year 70.3%) of infu-
sional 5-FU of our institute.17 After follow-up for 3 years, the
OS and DFS rates were 94.1% and 78.6%, respectively.
The failure pattern in our study was distant metastasis in
four patients. After preoperative chemoradiotherapy and
radical surgery, more intensive adjuvant treatment, such as
chemotherapy, should be considered for high-risk patients, to
achieve better disease control and improve OS.
Although good treatment responses, limited side effects, and
rare surgical complications were noted in this Phase II study, it
was conducted in a single institute and only included 20 patients.
Further randomized Phase III trials with larger cohorts are
suggested to demonstrate the benefit of the addition of oxali-
platin in preoperative chemoradiotherapy for rectal cancer.
In conclusion, preoperative chemoradiotherapy with oxa-
liplatin and tegafur-uracil was a well-tolerated treatment
regimen that achieved an excellent pCR in 40% of patients
with locally advanced mid-to-lower rectal cancer. Further tri-
als are needed to confirm the benefits of adding oxaliplatin in
preoperative chemoradiotherapy for rectal cancer.
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